Watch our 5-minute video on the advantages and considerations of LAIs compared with oral antipsychotics for the treatment of schizophrenia. Stream the video today!
Watch our 5-minute video on the advantages and considerations of LAIs compared with oral antipsychotics for the treatment of schizophrenia. Stream the video today!
As a healthcare professional in the mental health field, staying up-to-date is crucial. NPPsych Navigator offers clinical and educational resources to support your screening, diagnosis, and management of patients. Explore today!
As a healthcare professional in the mental health field, staying up-to-date is crucial. NPPsych Navigator offers clinical and educational resources to support your screening, diagnosis, and management of patients. Explore today!
The FDA and the DEA issued a joint statement on August 1, 2023 discussing the ongoing stimulant shortage highlighting several remediation strategies and potential alternatives as challenges continue to be worked through to help inform your...
The FDA and the DEA issued a joint statement on August 1, 2023 discussing the ongoing stimulant shortage highlighting several remediation strategies and potential alternatives as challenges continue to be worked through to help inform your...
Listen to Michele, an adult with ADHD, share her personal ADHD journey with various treatment experiences, including her current treatment with a nonstimulant medication.
Listen to Michele, an adult with ADHD, share her personal ADHD journey with various treatment experiences, including her current treatment with a nonstimulant medication.
Our latest video provides insights from Dr Price on extended‑release viloxazine compared with atomoxetine for attention-deficit/hyperactivity disorder (ADHD).
Our latest video provides insights from Dr Price on extended‑release viloxazine compared with atomoxetine for attention-deficit/hyperactivity disorder (ADHD).